In short
This article discusses the clinical trials of VE303, a novel drug containing live bacterial strains, including Clostridia, Cluster XIVa, Strain Relative Dorea_A Longicatena. The trials aim to evaluate VE303's effectiveness in preventing recurrent Clostridioides difficile infection (CDI), a serious bacterial infection affecting the gut. The study focuses on assessing the drug's safety, efficacy, and impact on patients' quality of life compared to a placebo.
At a glance
- Study Drug
- VE303 (containing live bacterial strains, including Clostridia, Cluster XIVa, Strain Relative Dorea_A Longicatena)
- Target Condition
- Recurrent Clostridioides difficile infection (CDI)
- Study Design
- Randomized, double-blind, placebo-controlled Phase 3 study
- Primary Objective
- Compare CDI recurrence rate at Week 8 between VE303 and placebo groups
- Secondary Objectives
- Assess safety, evaluate recurrence rates at 12 and 24 weeks, measure quality of life, study bacterial strain colonization
- Eligibility
- Patients aged 12+ (18+ in some countries) with confirmed CDI and specific risk factors
- Treatment Duration
- 14 days of oral VE303 or placebo after standard antibiotic therapy
- Follow-up Period
- 24 weeks
- Key Assessments
- CDI recurrence, adverse events, quality of life measures, bacterial strain detection and abundance
What is VE303?
VE303 is an innovative medical treatment being developed to combat Clostridioides difficile infection (CDI), a serious bacterial infection that affects the intestines. It is currently undergoing clinical trials to evaluate its effectiveness and safety.
VE303 is a capsule containing live bacteria, specifically designed to help restore the balance of good bacteria in your gut. These beneficial bacteria are carefully selected to fight against the harmful C. difficile bacteria.
How Does VE303 Work?
VE303 works by introducing a combination of eight different types of beneficial bacteria into your digestive system. These bacteria are known as live biotherapeutic products (LBPs). They are intended to colonize your gut and help restore a healthy balance of microorganisms, which can be disrupted during a C. difficile infection.
The bacteria in VE303 include various strains from the Clostridia and Bacilli families, such as:
- Clostridia, cluster XIVA, strain relative Clostridium_Q symbiosum, live
- Clostridia, cluster XIVA, strain relative Enterocloster bolteae, live
- Clostridia, cluster XIVA, strain relative Sellimonas intestinalis, live
- Clostridia, cluster IV, strain relative Flavonifractor plautii, live
- Clostridia, cluster XIVA, strain relative Blautia sp001304935, live
- Bacilli, cluster XVII, strain relative Clostridium_AQ innocuum, live
- Clostridia, cluster XIVA, strain relative Dorea_A longicatena, live
- Clostridia, cluster IV, strain relative Anaerotruncus colihominis, live
These bacteria are chosen for their potential to compete with and inhibit the growth of C. difficile, helping to prevent the recurrence of infection.
What Condition Does VE303 Treat?
VE303 is being developed to treat Clostridioides difficile infection (CDI). CDI is a serious condition that causes inflammation of the colon, leading to severe diarrhea and other intestinal problems. It often occurs after the use of antibiotics, which can disrupt the normal balance of bacteria in your gut.
The main goal of VE303 is to prevent the recurrence of CDI. Many patients who recover from an initial CDI episode are at risk of the infection coming back, which can be challenging to treat and potentially life-threatening.
Clinical Trial Details
VE303 is currently being studied in a Phase 3 clinical trial called the RestoratiVE303 Study. This is a large-scale study designed to evaluate how well VE303 works compared to a placebo (a dummy treatment) in preventing CDI recurrence.
The main objective of the trial is to compare the CDI recurrence rate at 8 weeks between participants who receive VE303 and those who receive a placebo. The study will also look at recurrence rates at 12 and 24 weeks.
Other important aspects of the study include:
- Assessing the safety of VE303
- Measuring how well the VE303 bacteria colonize the gut
- Evaluating the impact on quality of life and daily CDI symptoms
- Understanding how the colonization of VE303 bacteria relates to its effectiveness
Potential Benefits
If successful, VE303 could offer several potential benefits for patients with recurrent CDI:
- Reduced risk of CDI recurrence
- Improved quality of life
- Fewer CDI-related symptoms
- A non-antibiotic approach to managing CDI, which may help preserve the effectiveness of antibiotics for other infections
Administration and Dosage
VE303 is taken orally as a capsule. In the clinical trial, participants receive either VE303 or a placebo daily for 14 consecutive days. The maximum daily dose is 3 capsules, with a total of 42 capsules over the treatment period.
Who Can Participate in the Trial?
The trial is open to patients aged 12 years and older (18 years in some countries) who have had a confirmed CDI episode and at least one prior occurrence of CDI within the last 6 months. There are also specific criteria for older patients (75 years and above) and those with certain risk factors.
Participants must have completed a course of standard antibiotic therapy for their CDI and shown a successful clinical response before starting the trial.
Safety Considerations
As with any clinical trial, there are important safety considerations:
- The trial excludes people with certain medical conditions, including chronic diarrhea, celiac disease, inflammatory bowel disease, and recent major gastrointestinal surgery.
- Pregnant or breastfeeding women cannot participate.
- People with known allergies to any ingredients in VE303 are not eligible.
- The trial will closely monitor for any side effects or adverse events throughout the study period.
It's important to note that VE303 is still an investigational treatment. While it shows promise, its full safety profile and effectiveness are still being evaluated through this clinical trial.